Lieke Tweehuysen

Subjective Complaints as the Main Reason for Biosimilar Discontinuation After Open‐Label Transition From Reference Infliximab to Biosimilar Infliximab

Lieke Tweehuysen, Bart J. F. van den Bemt, Iris L. van Ingen et al. · Arthritis & Rheumatology · 2017 · 164 citations

Medicine, Internal Medicine, Pharmacotherapy +16

Open‐Label, Non‐Mandatory Transitioning From Originator Etanercept to Biosimilar <scp>SB</scp>4

Lieke Tweehuysen, Victor J B Huiskes, Bart J. F. van den Bemt et al. · Arthritis & Rheumatology · 2018 · 99 citations

Medicine, Pharmacology, Pharmacotherapy +12

The discriminative capacity of soluble Toll-like receptor (sTLR)2 and sTLR4 in inflammatory diseases

Jaap ten Oever, Matthijs Kox, Frank L. van de Veerdonk et al. · BMC Immunology · 2014 · 71 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17

Flares in Rheumatoid Arthritis Patients with Low Disease Activity: Predictability and Association with Worse Clinical Outcomes

Katie Bechman, Lieke Tweehuysen, Toby Garrood et al. · The Journal of Rheumatology · 2018 · 65 citations · Full text

Medicine, Clinical Sciences, Internal Medicine +17

Predictive value of serum calprotectin (S100A8/A9) for clinical response after starting or tapering anti-TNF treatment in patients with rheumatoid arthritis

Lieke Tweehuysen, Nathan den Broeder, Noortje van Herwaarden et al. · RMD Open · 2018 · 40 citations · Full text

Medicine, Clinical Sciences, Immunology +15